• Seattle Genetics Inc., of Bothell, Wash., inked a new antibody-drug conjugate (ADC) oncology collaboration with Bayer HealthCare, a unit of Bayer AG, of Leverkusen, Germany, in exchange for up-front and option exercise fees of up to $20 million, with the prospect of receiving up to $500 million in potential milestones, plus royalties on sales of any products stemming from the multitarget collaboration.